Roger Adsett
Chief Operating OfficerMr. Roger Adsett, MBA, has been an Independent Director at Definium Therapeutics, Inc. since January 29, 2026. He has been Chief Operating Officer of Insmed Incorporated since November 14, 2019. He served as Chief Commercial Officer of Insmed Incorporated since September 27, 2016 until November 14, 2019. Mr. Adsett is a healthcare industry veteran with experience and a proven track record of successful development and commercialization of innovative medicines at several biopharmaceutical companies. He serves as an Independent Director at Landos Biopharma, Inc. since March 8, 2022. Mr. Adsett has experience in the global biotechnology and pharmaceutical industry. Mr. Adsett also has extensive experience in Inflammatory Bowel Disease (IBD) and the GastrointestinaI (GI) therapeutic area, successfully launching both blockbuster and specialty brands. Mr. Adsett served as Senior Vice President and Head of Gastrointestinal and Internal Medicine Business Unit at Shire Plc since January 2015 to September 2016. Prior to that, Mr. Adsett served as Senior Vice President of Gastrointestinal Business Unit Leader at Shire from August 2008 to January 2015. From October 2005 to August 2008, Mr. Adsett served as General Manager of Oral IBD Products of the Gastroenterology Business Unit of Shire. From November 1994 to October 2005, Mr. Adsett held various marketing and commercial roles at AstraZeneca plc, a multinational pharmaceutical and biopharmaceutical company (AstraZeneca). Prior to his time at AstraZeneca, Mr. Adsett was a Senior Analyst at Accenture PLC. from September 1991 to November 1994. Mr. Adsett serves as a Director of Shire-Movetis NV. Earlier in his career, Mr. Adsett spent many years at AstraZeneca, where he held a variety of commercial leadership roles, including as marketing director for the U.S. launch of Nexium, a blockbuster therapy for gastroesophageal reflux disease and as global brand director for Symbicort®, a leading treatment for asthma and chronic obstructive pulmonary disease. Prior to AstraZeneca, he spent three years at Accenture. He also served on the Board of Directors of Landos Biopharma, Inc. from March 2022 until its acquisition by AbbVie in May 2024. Mr. Adsett holds an M.B.A. from The Wharton School at the University of Pennsylvania and a B.A. in English and Economics from Bucknell University.
Positions
- Company NameInsmed IncorporatedStock CodeINSMPositionChief Operating OfficerColleagues
- WHWilliam H. LewisPresident, CEO & Chairman
- MAMichael Alexander SmithChief Legal Officer & Corporate Secretary
- MFMartina FlammerChief Medical Officer
- BOBrendan O’LearySenior Vice President of Finance
- DRDavid R. BrennanLead Independent Director
- CACarol A. SchaferIndependent Director
- MSMelvin SharokyIndependent Director
- LLLeo LeeIndependent Director
